UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 107

Sortiert nach

Revisiting Estrogen for the Treatment of Endocrine-Resistant Breast Cancer: Novel Therapeutic Approaches

Cancers, 2023-07, Vol.15 (14), p.3647

2023

Volltextzugriff (PDF)

Protein kinase C α enhances migration of breast cancer cells through FOXC2-mediated repression of p120-catenin

BMC cancer, 2017-12, Vol.17 (1), p.832-832, Article 832

2017

Volltextzugriff (PDF)

Novel Selective Estrogen Receptor Downregulators (SERDs) Developed against Treatment-Resistant Breast Cancer

Journal of medicinal chemistry, 2017-02, Vol.60 (4), p.1325-1342

2017

Volltextzugriff (PDF)

Design and Synthesis of Basic Selective Estrogen Receptor Degraders for Endocrine Therapy Resistant Breast Cancer

Journal of medicinal chemistry, 2019-12, Vol.62 (24), p.11301-11323

2019

Volltextzugriff (PDF)

Cross-talk between Notch and the Estrogen Receptor in Breast Cancer Suggests Novel Therapeutic Approaches

Cancer research (Chicago, Ill.), 2008-07, Vol.68 (13), p.5226-5235

2008

Volltextzugriff (PDF)

Immunotherapeutic Approaches in Triple-Negative Breast Cancer: State of the Art and Future Perspectives

International journal of breast cancer, 2020-11, Vol.2020, p.1-9

2020

Volltextzugriff (PDF)

Novel Pyrrolopyridone Bromodomain and Extra-Terminal Motif (BET) Inhibitors Effective in Endocrine-Resistant ER+ Breast Cancer with Acquired Resistance to Fulvestrant and Palbociclib

Journal of medicinal chemistry, 2020-07, Vol.63 (13), p.7186-7210

2020

Volltextzugriff (PDF)

Stable Isotope-Resolved Metabolomic Differences between Hormone-Responsive and Triple-Negative Breast Cancer Cell Lines

International journal of breast cancer, 2018-01, Vol.2018, p.2063540-12

2018

Volltextzugriff (PDF)

Efferocytosis produces a prometastatic landscape during postpartum mammary gland involution

The Journal of clinical investigation, 2014-11, Vol.124 (11), p.4737-4752

2014

Volltextzugriff (PDF)

Overcoming Therapeutic Resistance of Triple Positive Breast Cancer with CDK4/6 Inhibition

International journal of breast cancer, 2018-01, Vol.2018, p.7835095-11

2018

Volltextzugriff (PDF)

Pharmacology and Molecular Mechanisms of Clinically Relevant Estrogen Estetrol and Estrogen Mimic BMI-135 for the Treatment of Endocrine-Resistant Breast Cancer

Molecular pharmacology, 2020-10, Vol.98 (4), p.364-381

2020

Volltextzugriff (PDF)

Exploring DNA methylation changes in promoter, intragenic, and intergenic regions as early and late events in breast cancer formation

BMC cancer, 2015-10, Vol.15 (1), p.816-816, Article 816

2015

Volltextzugriff (PDF)

G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer

Breast cancer research and treatment, 2020-04, Vol.180 (3), p.635-646

2020

Volltextzugriff (PDF)

Rapid Induction of the Unfolded Protein Response and Apoptosis by Estrogen Mimic TTC-352 for the Treatment of Endocrine-Resistant Breast Cancer

Molecular cancer therapeutics, 2021-01, Vol.20 (1), p.11-25

2021

Volltextzugriff (PDF)

Phase 1 study of TTC-352 in patients with metastatic breast cancer progressing on endocrine and CDK4/6 inhibitor therapy

Breast cancer research and treatment, 2020-10, Vol.183 (3), p.617-627

2020

Volltextzugriff (PDF)

Gene expression patterns in the human breast after pregnancy

Cancer prevention research (Philadelphia, Pa.), 2010-03, Vol.3 (3), p.301-311

2010

Volltextzugriff (PDF)

Breast-i Is an Effective and Reliable Adjunct Screening Tool for Detecting Early Tumour Related Angiogenesis of Breast Cancers in Low Resource Sub-Saharan Countries

International journal of breast cancer, 2018-01, Vol.2018, p.2539056-10

2018

Volltextzugriff (PDF)

Selective Human Estrogen Receptor Partial Agonists (ShERPAs) for Tamoxifen-Resistant Breast Cancer

Journal of medicinal chemistry, 2016-01, Vol.59 (1), p.219-237

2016

Volltextzugriff (PDF)

Endocrine Therapy-Resistant Breast Cancer Cells Are More Sensitive to Ceramide Kinase Inhibition and Elevated Ceramide Levels Than Therapy-Sensitive Breast Cancer Cells

Cancers, 2022-05, Vol.14 (10), p.2380

2022

Volltextzugriff (PDF)

Concordance between Immunohistochemistry and Microarray Gene Expression Profiling for Estrogen Receptor, Progesterone Receptor, and HER2 Receptor Statuses in Breast Cancer Patients in Lebanon

International journal of breast cancer, 2018-01, Vol.2018, p.8530318-6

2018

Volltextzugriff (PDF)

Retraction Note to: Extranuclear ERα is associated with regression of T47D PKCα-overexpressing, tamoxifen-resistant breast cancer

Molecular cancer, 2017-07, Vol.16 (1), p.121-121, Article 121

2017

Volltextzugriff (PDF)

PTK6 Activation at the Membrane Regulates Epithelial-Mesenchymal Transition in Prostate Cancer

Cancer research (Chicago, Ill.), 2013-09, Vol.73 (17), p.5426-5437

2013

Volltextzugriff (PDF)

Extranuclear ERα is associated with regression of T47D PKCα-overexpressing, tamoxifen-resistant breast cancer

Molecular cancer, 2013-05, Vol.12 (1), p.34-34

2013

Volltextzugriff (PDF)

Correlation of Oncotype DX Recurrence Score with Histomorphology and Immunohistochemistry in over 500 Patients

International journal of breast cancer, 2017-01, Vol.2017, p.1257078-6

2017

Volltextzugriff (PDF)

PTK6/BRK is expressed in the normal mammary gland and activated at the plasma membrane in breast tumors

Oncotarget, 2014-08, Vol.5 (15), p.6038-6048

2014

Volltextzugriff (PDF)

1 – 25 von 107

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(103)
Mit Volltextzugriff
(105)

Publikationsform

Sprache

Englisch
(107)
Japanisch
(11)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

International Journal Of Breast Cancer
(26)
Cancer Research
(23)
Molecular Cancer
(6)
Journal Of Medicinal Chemistry
(4)
Bmc Cancer
(3)
Carcinogenesis
(3)
Molecular Cancer Therapeutics
(3)
Oncogene
(3)
Breast Cancer Research And Treatment
(2)
Cancers
(2)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Revisiting Estrogen for the Treatment of Endocrine-Resistant Breast Cancer: Novel Therapeutic Approaches

Protein kinase C α enhances migration of breast cancer cells through FOXC2-mediated repression of p120-catenin

Novel Selective Estrogen Receptor Downregulators (SERDs) Developed against Treatment-Resistant Breast Cancer

Design and Synthesis of Basic Selective Estrogen Receptor Degraders for Endocrine Therapy Resistant Breast Cancer

Cross-talk between Notch and the Estrogen Receptor in Breast Cancer Suggests Novel Therapeutic Approaches

Immunotherapeutic Approaches in Triple-Negative Breast Cancer: State of the Art and Future Perspectives

Novel Pyrrolopyridone Bromodomain and Extra-Terminal Motif (BET) Inhibitors Effective in Endocrine-Resistant ER+ Breast Cancer with Acquired Resistance to Fulvestrant and Palbociclib

Stable Isotope-Resolved Metabolomic Differences between Hormone-Responsive and Triple-Negative Breast Cancer Cell Lines

Efferocytosis produces a prometastatic landscape during postpartum mammary gland involution

Overcoming Therapeutic Resistance of Triple Positive Breast Cancer with CDK4/6 Inhibition

Pharmacology and Molecular Mechanisms of Clinically Relevant Estrogen Estetrol and Estrogen Mimic BMI-135 for the Treatment of Endocrine-Resistant Breast Cancer

Exploring DNA methylation changes in promoter, intragenic, and intergenic regions as early and late events in breast cancer formation

G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer

Rapid Induction of the Unfolded Protein Response and Apoptosis by Estrogen Mimic TTC-352 for the Treatment of Endocrine-Resistant Breast Cancer

Phase 1 study of TTC-352 in patients with metastatic breast cancer progressing on endocrine and CDK4/6 inhibitor therapy

Gene expression patterns in the human breast after pregnancy

Breast-i Is an Effective and Reliable Adjunct Screening Tool for Detecting Early Tumour Related Angiogenesis of Breast Cancers in Low Resource Sub-Saharan Countries

Selective Human Estrogen Receptor Partial Agonists (ShERPAs) for Tamoxifen-Resistant Breast Cancer

Endocrine Therapy-Resistant Breast Cancer Cells Are More Sensitive to Ceramide Kinase Inhibition and Elevated Ceramide Levels Than Therapy-Sensitive Breast Cancer Cells

Concordance between Immunohistochemistry and Microarray Gene Expression Profiling for Estrogen Receptor, Progesterone Receptor, and HER2 Receptor Statuses in Breast Cancer Patients in Lebanon

Retraction Note to: Extranuclear ERα is associated with regression of T47D PKCα-overexpressing, tamoxifen-resistant breast cancer

PTK6 Activation at the Membrane Regulates Epithelial-Mesenchymal Transition in Prostate Cancer

Extranuclear ERα is associated with regression of T47D PKCα-overexpressing, tamoxifen-resistant breast cancer

Correlation of Oncotype DX Recurrence Score with Histomorphology and Immunohistochemistry in over 500 Patients

PTK6/BRK is expressed in the normal mammary gland and activated at the plasma membrane in breast tumors

Suchergebnisse filtern